Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents
Open Access
- 1 December 2023
- journal article
- research article
- Published by Elsevier in Annals of Hepatology
- Vol. 29 (2) , 101182
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart DiseaseNutrients, 2013
- Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysisBiomedical Reports, 2012
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has A Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling PathwayHepatology, 2010
- Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical ImplicationsHepatology, 2010
- Pathogenesis of non-alcoholic fatty liver diseaseQJM: An International Journal of Medicine, 2009
- Liver fat and lipid oxidation in humansLiver International, 2009
- ‘Endocrine NAFLD’ a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesisJournal of Hepatology, 2006
- The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitroBiochemical and Biophysical Research Communications, 2005
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001